Literature DB >> 26160188

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Elena B Volokhina1, Grethe Bergseth2, Nicole C A J van de Kar1, Lambertus P van den Heuvel3, Tom Eirik Mollnes4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26160188      PMCID： PMC4528083          DOI： 10.1182/blood-2015-03-637645

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  An international serum standard for application in assays to detect human complement activation products.

Authors:  Grethe Bergseth; Judith K Ludviksen; Michael Kirschfink; Patricia C Giclas; Bo Nilsson; Tom E Mollnes
Journal:  Mol Immunol       Date:  2013-06-17       Impact factor: 4.407

2.  Eculizumab fails to inhibit generation of C5a in vivo.

Authors:  Richard M Burwick; Nicholas R Burwick; Bruce B Feinberg
Journal:  Blood       Date:  2014-11-27       Impact factor: 22.113

3.  Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.

Authors:  Michael J Krisinger; Verena Goebeler; Zhen Lu; Scott C Meixner; Timothy Myles; Edward L G Pryzdial; Edward M Conway
Journal:  Blood       Date:  2012-07-16       Impact factor: 22.113

Review 4.  Fluid phase generation of terminal complement complex as a novel index of bioincompatibility.

Authors:  R Deppisch; V Schmitt; J Bommer; G M Hänsch; E Ritz; E W Rauterberg
Journal:  Kidney Int       Date:  1990-02       Impact factor: 10.612

5.  Generation of C5a in the absence of C3: a new complement activation pathway.

Authors:  Markus Huber-Lang; J Vidya Sarma; Firas S Zetoune; Daniel Rittirsch; Thomas A Neff; Stephanie R McGuire; John D Lambris; Roscoe L Warner; Michael A Flierl; Laszlo M Hoesel; Florian Gebhard; John G Younger; Scott M Drouin; Rick A Wetsel; Peter A Ward
Journal:  Nat Med       Date:  2006-05-21       Impact factor: 53.440

6.  Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

Authors:  Randi Fykse Hallstensen; Grethe Bergseth; Stian Foss; Steinar Jæger; Tobias Gedde-Dahl; Jan Holt; Dorte Christiansen; Corinna Lau; Ole-Lars Brekke; Elina Armstrong; Vedran Stefanovic; Jan Terje Andersen; Inger Sandlie; Tom Eirik Mollnes
Journal:  Immunobiology       Date:  2014-11-13       Impact factor: 3.144

7.  Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents.

Authors:  W Vogt; B Zimmermann; D Hesse; R Nolte
Journal:  Mol Immunol       Date:  1992-02       Impact factor: 4.407

8.  Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.

Authors:  J L Wagner; T E Hugli
Journal:  Anal Biochem       Date:  1984-01       Impact factor: 3.365
  8 in total
  9 in total

1.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Authors:  Monica Konar; Dan M Granoff
Journal:  Blood       Date:  2017-06-19       Impact factor: 22.113

2.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

3.  Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.

Authors:  Andreas Barratt-Due; Yngvar Fløisand; Hilde L Orrem; Ann K Kvam; Pål A Holme; Grethe Bergseth; Geir E Tjønnfjord; Tom E Mollnes
Journal:  Rheumatology (Oxford)       Date:  2016-04-22       Impact factor: 7.580

4.  C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.

Authors:  Elena Panayiotou; Eleni Fella; Revekka Papacharalambous; Stavros Malas; Maria Joao Saraiva; Theodoros Kyriakides
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

5.  Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent.

Authors:  Bärbel Rohrer; Ashley Frazer-Abel; Anthony Leonard; Rinki Ratnapriya; Tyson Ward; Alexandra Pietraszkiewicz; Elizabeth O'Quinn; Katherine Adams; Anand Swaroop; Bethany Jacobs Wolf
Journal:  Mol Vis       Date:  2019-02-08       Impact factor: 2.367

6.  Complement System Inhibition Modulates the Pro-Inflammatory Effects of a Snake Venom Metalloproteinase.

Authors:  Lygia Samartin Gonçalves Luchini; Giselle Pidde; Carla Cristina Squaiella-Baptistão; Denise V Tambourgi
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

7.  Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.

Authors:  Jan C Holter; Soeren E Pischke; Eline de Boer; Andreas Lind; Synne Jenum; Aleksander R Holten; Kristian Tonby; Andreas Barratt-Due; Marina Sokolova; Camilla Schjalm; Viktoriia Chaban; Anette Kolderup; Trung Tran; Torleif Tollefsrud Gjølberg; Linda G Skeie; Liv Hesstvedt; Vidar Ormåsen; Børre Fevang; Cathrine Austad; Karl Erik Müller; Cathrine Fladeby; Mona Holberg-Petersen; Bente Halvorsen; Fredrik Müller; Pål Aukrust; Susanne Dudman; Thor Ueland; Jan Terje Andersen; Fridtjof Lund-Johansen; Lars Heggelund; Anne M Dyrhol-Riise; Tom E Mollnes
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-17       Impact factor: 11.205

Review 8.  The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review.

Authors:  Anna Ruocco; Anna Sirico; Rubina Novelli; Silvia Iannelli; Shane Vontelin Van Breda; Diego Kyburz; Paul Hasler; Andrea Aramini; Pier Giorgio Amendola
Journal:  Front Cell Dev Biol       Date:  2022-08-08

9.  Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.

Authors:  Antonello Caruso; Jannik Vollmer; Matthias Machacek; Elod Kortvely
Journal:  PLoS Comput Biol       Date:  2020-10-02       Impact factor: 4.475
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.